The purpose of this research is to collect information about a newly developed, experimental computerized test. This test measures the ability to perform common daily activities that require thinking, memory, attention and language skills.
To qualify one must be at least age 55 and have a mild memory complaint. You are required to have a study partner who knows you well and can answer questions about your memory and daily activities.
You and your study partner will be paid for your study participation.Click to view our PDF brochure
This study is recruiting participants who are experiencing memory issues to develop a physical activity smartphone application for older adults.
To qualify, one must own a smartphone, have some difficulty with memory, have a family member/friend/caregiver who can attend sessions and test the app with you, and be over the age of 65.
If you are eligible, you will be paid up to $190 for your continued participation.Click to view our PDF brochure
The purpose of this study is to learn how medical conditions affecting the blood vessels of the brain such as high blood pressure, cholesterol, or high blood sugar may be related to developing Alzheimer disease in the future. This study is designed to examine biological markers in the blood and spinal fluid, and changes in the brain’s structure. Our goal is to use the information collected from this study for future programs that will reduce the risk for memory loss or Alzheimer disease.
English- or Spanish-speaking men and women of 60 years or older are eligible for the HVHB study. Participants will receive medical examinations, tests of memory and daily function, MRI brain scans, blood tests, and a test of cerebral spinal fluid.
Study participants receive a small financial compensation for visits to USC.
Please call Meseret Alemu at (323) 442-7555 or Nadine Diaz, MSW at (323) 442-7603 for more information.
The goal of this study is to learn about the biological changes of normal aging, memory loss, and Alzheimer’s related conditions through brain donation and autopsy. Participants will generally visit us at USC every year for memory testing, a brief medical history, and review of function and medication changes. Participants in the Brain Research Study can be in our other studies as well and may receive brain MRI or PET scans.
Potential volunteers include older people with no memory impairments, mild impairments, or mild Alzheimer’s disease who are willing to visit us usually yearly and to donate their brain when the time comes. The autopsy focuses on the brain and provides us with scientific information about aging, other conditions such as atherosclerosis, inflammation, and mini-strokes.
We will send a report of our findings to a family member soon afterwards. The autopsy does not complicate a funeral or affect a viewing. There are no charges for the study procedures, autopsy, neuropathology report or discussions with the family.
If you are interested in becoming a participant in this very important study, then please contact John Danner LCSW at JohnJ.Danner@med.usc.edu or Nadine Diaz MSW at Nadine.Diaz@med.usc.edu or call us at 323-442-7600 for information.
The goal of this study is to examine the relationship between physical or mental activity and brain health in a non-drug, behavioral clinical trial. Eligible participants will be involved in a 6-month, at-home, healthy living program involving physical or mental activity. Participants will visit USC’s Health Sciences Campus to complete physical testing, brain scans, memory testing, questionnaires, and medical history intake. Potential volunteers include those 60-80 years of age who are able to walk without assistance and are willing to visit us three times over a 12 month period.
Participants will be provided with a wearable fitness tracker which records the amount of activity throughout the day, and an MRI scan of their brain. There are no charges for the study procedures, at home visits, or materials. Participants may receive compensation for their time.
If you are interested in becoming a participant in this aging and brain research study, please contact Lisette Isenberg at Lisette.Isenberg@loni.usc.edu or call 323-442-0141 for more information; or Judy Pa, PhD, USC Stevens Neuroimaging and Informatics Institute at firstname.lastname@example.org
This NIH-funded study is focused on understanding Alzheimer’s in persons of Mexican Mestizo origin and its genetics as different types may respond differentially to treatments. In this study we apply the Human Connectome Protocol (HCP), a special kind of MRI procedure, to persons with or at-risk for genetic forms of AD and persons of Mexican descent. By applying the HCP protocol along with PET scans, we are testing to see whether the spread of an abnormal protein called tau is critical to the causes of Alzheimer’s and whether it is a special subtype of the illness. Participants will undergo approximately 4 days of assessment with cognitive evaluations, a neurological examination, 2 MRI sessions, a PET scan, and transcranial magnetic stimulation. They are compensated for the time involved and travel expenses.
For more information, please contact Lucy Montoya at (323) 723-2599 or Dr. John Ringman at (323) 442-0321.
The Alzheimer Disease Neuroimaging Initiative (ADNI) is inviting volunteers to join our 800 current participants in the third phase of this multiyear study. ADNI 3 is studying changes in cognition, function, brain structure, and biomarkers.
To qualify one must be: over age 55, in good general health, cognitively normal, and fluent in English or Spanish. ADNI 3 will also be recruiting those with mild memory problems and those who have mild Alzheimer disease. Participants must be willing to undergo in-clinic assessments, memory testing and other test procedures, and have a study partner who can accompany them to clinic visits.
Qualified participants may receive physical and neurological exams, cognitive testing, MRI scans and PET brain scans.
For further information, please contact us:
Nadine Diaz, MSW (Nadine.Diaz@med.usc.edu)
This study is seeking volunteers without significant memory impairment to help develop new on-line measures of cognition and everyday function.
To qualify, one must speak English and be between the ages of 60-85. Participants must have a study partner who is willing to participate in the study.
Compensation is provided for time and effort participating.Click to view our PDF brochure
The Escitalopram for Agitation in Alzheimer’s study is being conducted to determine if a study drug, given as a pill, can safely and effectively reduce the symptoms of agitation and aggression in people with Alzheimer’s disease.
To qualify one must have a diagnosis of Alzheimer’s, experience frequent agitation or aggression, and be available for 6 months of follow-up. Participants must have a caregiver who spends several hours per week with him/her and is willing to accompany the participant to study visits.
Participants and caregivers will receive counseling and materials to help manage agitation.Click to view our PDF brochure
The T2 Protect AD Study is a clinical trial testing the investigational drug Troriluzole for people with Alzheimer’s disease (AD). The USC Alzheimer Disease Research Center is testing how well a drug can protect against, or slow down, memory and thinking problems that increase as Alzheimer’s disease progresses. The research team is looking for volunteers (ages 50 to 85) who have mild to moderate Alzheimer’s Disease to join our study. A potential participant will first go through a screening process to see if they are eligible to take part in the clinical trial. If you eligible and choose to join the study, participation in the study will take 48 weeks. Study participants visit the study clinic 9 times after enrollment in the trial.
For more information, please contact the Project Director, Karen Dagerman at (323) 442-7600 or email at email@example.com .
This randomized clinical trial tests the effectiveness of omega-3 supplements in individuals at risk for Alzheimer’s. The study will help us advance our understanding of Alzheimer disease and propose methods to reduce cognitive decline in high-risk populations. We invite you or someone you know who is interested in participating to call us for more information. You may be eligible for this study if you are at least 60 years of age and not taking omega-3 supplements. The study compares placebo or 2 grams of DHA over two years. It involves measuring omega-3 blood levels, brain imaging, and memory tests in 5 visits during the two-year period.
To learn more or to participate, please contact us at (323) 489-4896 and ask for Laura Serna, Research Coordinator or Nicholas Choe, research assistant; or call Nadine Diaz, MSW (323) 442-7603. You can also email the study at firstname.lastname@example.org or reach Dr. Hussein Yassine directly at email@example.com .
We are conducting an early phase study to evaluate the safety and effect of an experimental drug, allopregnanolone (Allo), on memory. This is a 16-week study to compare Allo to placebo. The appointments will consist of cognitive assessments, brain scans, and study-related care.
To qualify one must be age 55 or older, and diagnosed with mild cognitive impairment (MCI) or mild Alzheimer disease. Participants will receive physical examinations, cognitive testing and MRI scans (brain imaging), and assistance with transportation to appointments.
For further information: http://clinicaltrials.gov/show/NCT02221622
Contact: USC Alzheimer Disease Research Center (ADRC)
Attn: Gerson Hernandez (firstname.lastname@example.org) or (323) 865-ALLO (2556) or (323) 442-7600.
The Anti-Amyloid Treatment in Asymptomatic Alzheimer study (the A4 study) is for older individuals, ages 65 to 85, who may be at risk for memory loss due to Alzheimer disease (AD). We are investigating a new drug intervention that may reduce the impact of a protein known as “amyloid” or “beta amyloid” forming plaques in the brain. Scientists believe that accumulation of amyloid in the brain may play a key role in the eventual development of AD-related memory loss. The A4 anti-amyloid investigational drug targets amyloid build-up in the brain with the aim of slowing memory loss associated with the development of AD.
Am I eligible?
For further information, please contact us:
Nadine Diaz, MSW (Nadine.Diaz@med.usc.edu)